The RNA-Targeted Small Molecules Market Size is valued at USD 2.24 billion in 2023 and is predicted to reach USD 3.60 billion by the year 2031 at a 6.29% CAGR during the forecast period for 2024-2031.
RNA-targeted small molecules represent a category of medicines engineered to specifically attach to RNA molecules and alter their activity, as opposed to the conventional strategy of targeting proteins in drug development. RNA-targeted small molecules open up new avenues for creative approaches to illness treatment by altering RNA activity. Indeed, a number of diseases, including viral infections, cancers, and genetic disorders, for which conventional therapies are usually useless, have shown considerable promise when treated with this innovative strategy.
As their capacity to directly disrupt the RNA sequences linked to the illness, these small molecules would provide a therapeutic strategy that is far more targeted and tailored than what is achievable with traditional treatments. The RNA-targeted small molecules market is stimulated by rising research and investment in RNA-targeted treatments. By modifying RNA function, splicing, or translation, RNA-targeted small molecules open up new therapeutic avenues for the treatment of hereditary and chronic illnesses.
Additionally, a rise in incidences of cancer and genetic abnormalities, as well as an increase in research and development efforts, have a significant impact on the RNA-targeted small molecules market's growth. As RNA-targeting therapeutics progress, it is anticipated that they will serve as a foundation for contemporary therapeutic approaches and present a significant commercial opportunity for research institutes and pharmaceutical businesses.
The RNA-targeted small molecules market is segmented based on product & service, assay type, indication, and end-user. The product & service segment includes mRNA translation regulation, indirect RNA targeting-epitranscriptomics, RNA Splicing Modification and Direct RNA Targeting. By application, the market comprises drug discovery, oncology research and disease identification. As per the end-user, the market is divided into hospitals, research laboratories, contract research organizations and pharmaceutical and biotechnology companies.
The direct RNA targeting category is expected to lead with a significant market share in 2023. Investigation and integration into clinical practice are necessary for the target RNA, one of the direct therapy alternatives. Small compounds that have been engineered to act with RNA molecules and change their expression, stability, or function are referred to as that category. The creation of tiny molecules for use in extremely selective treatments that target the fundamental causes of disease and lower the possibility of off-target consequences is what has led to the focus and dedication to direct RNA targeting. Large R&D expenditure is devoted to the development of tiny molecule optimization for effective binding and RNA structural modification.
With the ability to investigate and validate novel therapeutic targets, the advent of RNA-targeted small molecules in drug discovery is displacing the conventional approaches to new therapeutic development. This procedure is now much more efficient due to high-throughput screening technologies, which evaluate thousands of compounds simultaneously. In addition, small compounds that target RNA are frequently used in conjunction with other omics techniques, such as proteomics and genomics, to fully characterize the underlying mechanisms of disease as well as potential targets for treatment. This integrated strategy highlights the significance of RNA-targeted small molecules in contemporary drug discovery and encourages the creation of more potent and focused treatments.
The North American RNA-targeted small molecules market is expected to report the prominent market share in revenue in the near future because of the significant concentration of the pharmaceutical and biotechnology firms in the area and the sizable government support for life sciences R&D. Similar to this, it is expected that during the course of the forecast period, the RNA-targeted small molecules market will see profitable growth due to the rising prevalence of chronic diseases and the growing requirement for RNA-targeted small molecules.
The creation of novel cures and treatments depends on these technologies. Additionally, a sizable and quickly growing population is anticipated to propel market expansion during the projected period, as will rising government funding for healthcare infrastructure. In addition, Asia Pacific is projected a rapid growth in the global RNA-targeted small molecules market. The rising incidence of illnesses like cancer, heart problems, and neurological conditions is driving this region's market. The need for novel RNA-targeted small molecules has grown as a result.
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 2.24 Bn |
|
Revenue Forecast In 2031 |
USD 3.60 Bn |
|
Growth Rate CAGR |
CAGR of 6.29% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Product & Service, Assay Type, Indication, And End-User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Anima Biotech Inc., AstraZeneca, Nymirum Inc., Pfizer, Expansion Therapeutics, Bentham Science, PharmTech, Accent Therapeutics, Bristol-Myers Squibb, Novartis, and Others. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global RNA-Targeted Small Molecules Market Snapshot
Chapter 4. Global RNA-Targeted Small Molecules Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2031
4.8. Global RNA-Targeted Small Molecules Market Penetration & Growth Prospect Mapping (US$ Mn), 2023-2031
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.10. Use/impact of AI on RNA-Targeted Small Molecules Industry Trends
Chapter 5. RNA-Targeted Small Molecules Market Segmentation 1: By Product & Service, Estimates & Trend Analysis
5.1. Market Share by Product & Service, 2023 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Product & Service:
5.2.1. mRNA Translation Regulation
5.2.2. Indirect RNA Targeting-Epitranscriptomics
5.2.3. RNA Splicing Modification
5.2.4. Direct RNA Targeting
Chapter 6. RNA-Targeted Small Molecules Market Segmentation 2: By Application, Estimates & Trend Analysis
6.1. Market Share by Application, 2023 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Applications:
6.2.1. Drug Discovery
6.2.2. Oncology Research
6.2.3. Disease Identificatio
Chapter 7. RNA-Targeted Small Molecules Market Segmentation 3: By End user, Estimates & Trend Analysis
7.1. Market Share by End user, 2023 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following End users:
7.2.1. Hospitals
7.2.2. Research Laboratories
7.2.3. Contract Research Organizations
7.2.4. Pharmaceutical and Biotechnology Companies
Chapter 8. RNA-Targeted Small Molecules Market Segmentation 6: Regional Estimates & Trend Analysis
8.1. Global RNA-Targeted Small Molecules Market, Regional Snapshot 2023 & 2031
8.2. North America
8.2.1. North America RNA-Targeted Small Molecules Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
8.2.1.1. US
8.2.1.2. Canada
8.2.2. North America RNA-Targeted Small Molecules Market Revenue (US$ Million) Estimates and Forecasts by Product & Service, 2024-2031
8.2.3. North America RNA-Targeted Small Molecules Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
8.2.4. North America RNA-Targeted Small Molecules Market Revenue (US$ Million) Estimates and Forecasts by End user, 2024-2031
8.3. Europe
8.3.1. Europe RNA-Targeted Small Molecules Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
8.3.1.1. Germany
8.3.1.2. U.K.
8.3.1.3. France
8.3.1.4. Italy
8.3.1.5. Spain
8.3.1.6. Rest of Europe
8.3.2. Europe RNA-Targeted Small Molecules Market Revenue (US$ Million) Estimates and Forecasts by Product & Service, 2024-2031
8.3.3. Europe RNA-Targeted Small Molecules Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
8.3.4. Europe RNA-Targeted Small Molecules Market Revenue (US$ Million) Estimates and Forecasts by End user, 2024-2031
8.4. Asia Pacific
8.4.1. Asia Pacific RNA-Targeted Small Molecules Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
8.4.1.1. India
8.4.1.2. China
8.4.1.3. Japan
8.4.1.4. Australia
8.4.1.5. South Korea
8.4.1.6. Hong Kong
8.4.1.7. Southeast Asia
8.4.1.8. Rest of Asia Pacific
8.4.2. Asia Pacific RNA-Targeted Small Molecules Market Revenue (US$ Million) Estimates and Forecasts by Product & Service, 2024-2031
8.4.3. Asia Pacific RNA-Targeted Small Molecules Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
8.4.4. Asia Pacific RNA-Targeted Small Molecules Market Revenue (US$ Million) Estimates and Forecasts By End user, 2024-2031
8.5. Latin America
8.5.1. Latin America RNA-Targeted Small Molecules Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
8.5.1.1. Brazil
8.5.1.2. Mexico
8.5.1.3. Rest of Latin America
8.5.2. Latin America RNA-Targeted Small Molecules Market Revenue (US$ Million) Estimates and Forecasts by Product & Service, 2024-2031
8.5.3. Latin America RNA-Targeted Small Molecules Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
8.5.4. Latin America RNA-Targeted Small Molecules Market Revenue (US$ Million) Estimates and Forecasts by End user, 2024-2031
8.6. Middle East & Africa
8.6.1. Middle East & Africa RNA-Targeted Small Molecules Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
8.6.1.1. GCC Countries
8.6.1.2. Israel
8.6.1.3. South Africa
8.6.1.4. Rest of Middle East and Africa
8.6.2. Middle East & Africa RNA-Targeted Small Molecules Market Revenue (US$ Million) Estimates and Forecasts by Product & Service, 2024-2031
8.6.3. Middle East & Africa RNA-Targeted Small Molecules Market Revenue (US$ Million) Estimates and Forecasts by application, 2024-2031
8.6.4. Middle East & Africa RNA-Targeted Small Molecules Market Revenue (US$ Million) Estimates and Forecasts by End user, 2024-2031
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. AstraZeneca
9.2.1.1. Business Overview
9.2.1.2. Key Product/Service Offerings
9.2.1.3. Financial Performance
9.2.1.4. Geographical Presence
9.2.1.5. Recent Developments with Business Strategy
9.2.2. Pfizer
9.2.3. Bentham Scienc
9.2.4. PharmTech
9.2.5. Nymirum Inc.
9.2.6. Accent Therapeutics
9.2.7. Anima Biotech Inc.
9.2.8. Expansion Therapeutics
9.2.9. Bristol-Myers Squibb
9.2.10. Novartis
9.2.11. Other Market Players
RNA-Targeted Small Molecules Market By Product & Service-
RNA-Targeted Small Molecules Market By Application-
RNA-Targeted Small Molecules Market By End-User-
RNA-Targeted Small Molecules Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
